Before any payout should be considered to anyone I would prefer...

Before any payout should be considered to anyone I would prefer to see some assessment of a possible Phosphagenics arbitration win.
From my laypersons point of view I have seen enough evidence of attempted IP theft,dodgy fiddles with priority patent dates and priority art etc to suggest POH have good reasons for an arbitration case.
What shareholders have no knowledge of is what was going on behind the scenes with POH and Mylan in 2015 leading up to the arbitration action.I suspect that it is in this period is where most of the action launched directly against Mylan has been found necessary.
The following quote is taken from the October 2015 newsletter just two months before arbitration action was initiated:
"Mylan continues to progress the development of their TPM® injectable and towards a regulatory file in the near future at which time we will update the market".
The speed with which major pharmaceutical companies like Teva,Pfizer,Fresenius Kabi,Sagent and MYLAN[2018] took up the generic version of Cubicin after it was possible in June 2016 also suggests a possible loss of income to POH with their daptomycin injectable on an ongoing basis.
Just my thoughts at this time.
Kens